Inhibrx, Inc.

NasdaqGM:INBX Stock Report

Market Cap: US$1.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Inhibrx Past Earnings Performance

Past criteria checks 0/6

Inhibrx's earnings have been declining at an average annual rate of -37%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been declining at an average rate of 37.9% per year.

Key information

-36.97%

Earnings growth rate

-15.31%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate-37.94%
Return on equity-2,344.01%
Net Margin-15,207.80%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Seeking Alpha • Apr 22

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue

Summary Inhibrx Biosciences, Inc. has surged nearly 40% amid rumors of Big Pharma interest in joint spinoffs of INBRX-106 and possibly a second asset. Ozekibart’s Phase 2 data in chondrosarcoma showed a 52% risk reduction in progression or death, positioning INBX as a first-mover in an unmet oncology market. INBRX-106, in combination with Keytruda, is advancing through Phase 2/3 trials, with key data readouts and potential spinoff partnerships as near-term catalysts. Despite strong upside potential and a $300 price target from Stifel, INBX financing remains a risk, with upcoming BLA submissions and pivotal data as critical inflection points. Read the full article on Seeking Alpha
Seeking Alpha • Nov 05

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Summary INBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing promising early results but faces market skepticism due to past failures of similar molecules. Financially, INBX is well-funded with over $200 million in cash and last reported income of $2 billion, providing a potential cash runway through 2025. Given the promising pipeline and strong financial position, I am tentatively optimistic about INBX and recommend a "Buy" rating. Read the full article on Seeking Alpha
Seeking Alpha • Jun 07

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Summary Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42 million by 2032. INBRX-106 is a hexavalent drug being developed for the treatment of patients with multiple solid tumor types. The global solid tumor therapeutics market is expected to reach $885.44 billion by 2033. Read the full article on Seeking Alpha
Analysis Article • May 13

Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Oct 03

Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

Inhibrx (NASDAQ:INBX) shares fell 8% in after-hours trading Monday after announcing it will hold a webcast on Tuesday morning to discuss the regulatory pathway for INBRX-101 for alpha-1 antitrypsin deficiency (AATD). AATD is an orphan disease affecting ~100K people in the US. It is characterized by low levels of the alpha-1 antitrypsin ("AAT") protein, which causes loss of lung tissue and function, and decreased life expectancy. INBRX-101 is a recombinant human AAT-Fc fusion protein designed to maintain levels of AAT with less frequent dosing compared to currently available therapies. Seeking Alpha's Quant Rating views Inhibrx (INBX) as a hold with high marks for momentum and growth.
Seeking Alpha • Jun 10

Inhibrx: Potential To Move To Registration Study With INBRX-101

Positive results have been released thus far from a phase 1 study using INBRX-101 for the treatment of patients with Alpha-1 Antitrypsin Deficiency. It is expected that the Alpha-1 Antitrypsin Deficiency Augmentation therapy market could reach $1.95 billion by 2026. If FDA gives green light to Inhibrx, then it should be able to initiate a pivotal registration study using INBRX-101 for patients with Alpha-1 Antitrypsin Deficiency 2nd half of 2022. INBRX-109, INBRX-106, INBRX-105, and INBRX-121 are 4 additional drugs in the pipeline being advanced as treatments for cancer; All 4 of these drugs plus INBRX-101 utilize the company's Single-domain antibody technology platform.
Analysis Article • Mar 23

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Inhibrx, Inc...

Revenue & Expenses Breakdown

How Inhibrx makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:INBX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 242-271330
31 Dec 232-241290
30 Sep 230-189270
30 Jun 231-172240
31 Mar 231-163220
31 Dec 222-145210
30 Sep 225-125190
30 Jun 227-111170
31 Mar 227-94140
31 Dec 217-82120
30 Sep 217-78110
30 Jun 2111-78100
31 Mar 2113-7580
31 Dec 2013-7670
30 Sep 2010-7560
30 Jun 206-7460
31 Mar 206-6860
31 Dec 1913-5160
30 Sep 1915-4060
30 Jun 1915-3060
31 Mar 1914-2650
31 Dec 189-3150
30 Sep 187-3540
31 Dec 178-1930
31 Dec 167-820

Quality Earnings: INBX is currently unprofitable.

Growing Profit Margin: INBX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: INBX is unprofitable, and losses have increased over the past 5 years at a rate of 37% per year.

Accelerating Growth: Unable to compare INBX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).

Return on Equity

High ROE: INBX has a negative Return on Equity (-2344.01%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/31 15:41
End of Day Share Price 2024/05/29 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inhibrx, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Reni BenjaminCitizens JMP Securities, LLC
Joshua SchimmerEvercore ISI